Kura Oncology, Inc.

  • Safety Score
  • Market Cap $829.58M
  • PE -4
  • Debt $9.47M
  • Cash $49.48M
  • EV $789.57M
  • FCF -$169.24M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$197.55M
ROE-47%
FCF-$169.24M
Equity$423.77M
Growth Stability1
PE-4.2
PB1.96
P/FCF-4.9
Price/Cash0.06
Debt/Equity0.02
Debt/FCF-0.06
Equity CAGR34%
Earnings Growth YoY41%
Earnings Growth QoQ7%
Equity CAGR 5Y8%
Equity CAGR 3Y-2%
Market Cap$829.58M
Assets$478.84M
Total Debt$9.47M
Cash$49.48M
Shares Outstanding77.75M
EV789.57M
Safety Score65%
Working Capital422.82M
Current Ratio11.47
Shares Growth 3y7%
Equity Growth QoQ-9%
Equity Growth YoY-1%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has a lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States.

SEC Filings

Direct access to Kura Oncology, Inc. (KURA) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Kura Oncology, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Kura Oncology, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Kura Oncology, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Kura Oncology, Inc..

= -$1.7B
012345678910TV
fcf-$169M-$169M-$169M-$169M-$169M-$169M-$169M-$169M-$169M-$169M-$169M-$1.7B
DCF-$154M-$140M-$127M-$116M-$105M-$96M-$87M-$79M-$72M-$65M-$652M
Value-$1.7B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Net Margins-----------
ROA-----------
ROE--28%-48%-44%-38%-29%-15%-26%-32%-38%-47%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Debt over FCF---------0.08-0.07-0.06
Debt over Equity-13.16-0.130.110.050.040.02-0.020.020.02
Growth Stability----------1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth-----------
Earnings YoY growth-11K%22%29%71%4%42%46%4%12%-
Equity YoY growth--53K%-31%40%102%36%179%-17%-17%-5%8%
FCF YoY growth-------47%5%13%-